BioSpace News Archive

Uvax Bio, LLC, a privately held, preclinical-stage vaccine company, announced that the International Union of Pure and Applied Chemistry has selected the glycan trimming technology used by Prof. Jiang Zhu of Scripps Research, Co-founder and Chief Scientific Officer of Uvax Bio in his innovative design of HIV-1 vaccines to improve immune recognition as one of the Top Ten Emerging Technologies in Chemistry for 2023.

Mirion, a leading provider of advanced radiation safety solutions, announced a philanthropic partnership with RAD-AID International to help bring radiology and radiation safety education and capabilities to underserved populations around the world.

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”) reported that a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas.

Blue-Zone Technologies Ltd. announced it has signed a definitive collaboration agreement with Class 1 Incorporated, Canada’s leading medical gas and centralized anesthetic capture equipment manufacturer, distributor and service provider.

Reset Pharmaceuticals, Inc., a privately held biotechnology company focused on the development of innovative treatments to address mental health conditions related to life-altering diseases, announces that the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration regarding its Investigational New Drug application for its oral psilocybin product candidate, RSTP1000, in demoralization syndrome.

Serva Energy’s sample measurement of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory.

HuidaGene Therapeutics today announced the first patient has been dosed in the multinational, master-protocol Phase 1/2a clinical trial (NCT05906953; CTR20232920) of HG004 gene therapy drug, or the STAR (Safety and efficacy Trial of HG004 for leber congenital Amaurosis related to Rpe65 gene mutations) study, an adeno-associated virus 9 (AAV9) gene replacement therapy candidate for the treatment of inherited retinal dystrophies caused by RPE65 mutations (RPE65-IRD).

BioAro Inc., an innovative biotechnology company headquartered in downtown Calgary, Canada, is on a mission to revolutionize the approach to Irritable Bowel Syndrome (IBS) treatment by facilitating worldwide access to microbiome testing and telemedicine.

Nicklaus Children’s Hospital announced it has treated its first patient with ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy for Duchenne muscular dystrophy.

Nortech Systems Incorporated, a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products announced two new members were elected to Nortech’s board of directors.